Literature DB >> 2686547

Effects on oral and intestinal microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients.

M Giuliano1, A Pantosti, G Gentile, M Venditti, W Arcese, P Martino.   

Abstract

We monitored the modifications of oral and intestinal microfloras of 10 allogeneic bone marrow recipients who received randomly either norfloxacin or pefloxacin (400 mg three times a day) as selective decontamination for infection prevention. After 1 week of treatment, in all patients members of the family Enterobacteriaceae were no longer detectable and in all but one pefloxacin-treated patient enterococci were also eliminated in the intestine. The anaerobic flora was not affected, with the exception of Bacteroides spp., markedly reduced after treatment with pefloxacin. In most patients the most striking effect was the increase in staphylococcal counts. These strains were found to be resistant to both quinolones in the study. Less consistent changes were observed in oral flora. No relevant difference could be demonstrated between the two regimens on bacterial counts either in feces or in saliva. This study shows the efficacy of both quinolones in eradicating gram-negative bacilli in the alimentary tract of bone marrow transplant patients; however, the finding of the overgrowth of resistant gram-positive organisms during treatment with these agents deserves further evaluation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2686547      PMCID: PMC172742          DOI: 10.1128/AAC.33.10.1709

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Comparative in vitro activities of new fluorinated quinolones and other antibiotics against coagulase-negative Staphylococcus blood isolates from neutropenic patients, and relationship between susceptibility and slime production.

Authors:  M Venditti; C Santini; P Serra; A Micozzi; G Gentile; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

Review 3.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

4.  Selective suppression of alimentary tract microbial flora as prophylaxis during granulocytopenia.

Authors:  M T Hargadon; V M Young; S C Schimpff; J C Wade; G E Minah
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

5.  Antimicrobial prophylaxis against infection in neutropenic patients.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

6.  Infection prevention during profound granulocytopenia. New approaches to alimentary canal microbial suppression.

Authors:  S C Schimpff
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

7.  Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy.

Authors:  D J Winston; D V Dudnick; M Chapin; W G Ho; R P Gale; W J Martin
Journal:  Arch Intern Med       Date:  1983-01

8.  In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.

Authors:  A M Clarke; S J Zemcov; M E Campbell
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

9.  Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.

Authors:  M Rozenberg-Arska; A W Dekker; J Verhoef
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

10.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

Authors:  J C Wade; S C Schimpff; K A Newman; P H Wiernik
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391

View more
  7 in total

Review 1.  Colonization resistance.

Authors:  E J Vollaard; H A Clasener
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 2.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Species identification and detection of oxacillin resistance in coagulase-negative Staphylococcus blood isolates from neutropenic patients.

Authors:  M Venditti; S Santilli; P Petasecca Donati; A Micozzi; G Gentile; P Martino
Journal:  Eur J Epidemiol       Date:  1991-11       Impact factor: 8.082

5.  Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Authors:  G H Talbot; P A Cassileth; L Paradiso; R Correa-Coronas; L Bond
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

6.  Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.

Authors:  J Carratala; A Fernandez-Sevilla; F Tubau; M A Dominguez; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.

Authors:  A Micozzi; M Nucci; M Venditti; G Gentile; C Girmenia; G Meloni; P Martino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.